Booz Allen Hamilton
BAH
$79.91
+1.56%
Booz Allen Hamilton Holding Corporation is a leading global consulting firm specializing in technology solutions for the defense, intelligence, and civilian sectors, with a core focus on artificial intelligence, cybersecurity, and digital transformation. The company is a dominant player in the government services market, leveraging its deep domain expertise and long-term client relationships to serve as a trusted advisor to U.S. federal agencies. The current investor narrative is heavily influenced by the U.S. Department of Defense's strategic pivot towards AI and autonomous systems, as highlighted in recent news, which positions Booz Allen to capture significant, high-margin contracts, though this is juxtaposed against recent financial results showing revenue contraction and a challenging stock price performance.…
BAH
Booz Allen Hamilton
$79.91
Related headlines
Investment Opinion: Should I buy BAH Today?
Rating: Hold. The core thesis is that BAH presents a high-risk, high-potential-reward situation where compelling long-term strategic positioning is currently overshadowed by verifiable near-term fundamental weakness, warranting caution until a growth inflection point is visible.
The Hold rating is supported by several specific data points: 1) The forward P/E of 12.6x is historically low for the company, suggesting bad news is priced in. 2) The balance sheet is exceptionally strong with a D/E of 0.18 and $933M in TTM FCF. 3) However, revenue growth is deeply negative at -10.2% YoY. 4) Analyst sentiment is neutral-to-bearish, with recent downgrades, indicating a lack of near-term catalysts. The stock's 39% annual decline reflects this dichotomy.
The two biggest risks invalidating a future upgrade are persistent revenue contraction and further margin erosion. This Hold would upgrade to a Buy if quarterly revenue returns to positive YoY growth and gross margins stabilize above 52%. It would downgrade to a Sell if revenue decline accelerates beyond 15% YoY or if the stock breaks decisively below its 52-week low of $68.84 on sustained volume. Relative to its own history, the stock appears fairly valued to slightly undervalued given the growth headwinds, but it is not yet a clear bargain without evidence of a turnaround.
Sign up to view all
BAH 12-Month Price Forecast
The assessment is neutral with medium confidence. The data presents a bifurcated picture: terrible momentum in growth and price, but underlying financial resilience and a potentially discounted valuation. The stock is in a 'show me' state; the bullish AI narrative lacks confirmation in current financials. The stance would upgrade to bullish on concrete evidence of revenue growth reacceleration and margin stabilization, likely visible in the next two quarterly reports. It would turn bearish if the stock loses its key technical support level on high volume, signaling a breakdown of the current consolidation range.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Booz Allen Hamilton's 12-month outlook, with a consensus price target around $103.88 and implied upside of +30.0% versus the current price.
Average Target
$103.88
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$64 - $104
Analyst target range
The stock is covered by 10 analysts, with consensus sentiment leaning neutral to bearish, as evidenced by recent institutional ratings including 'Hold', 'Neutral', 'Sell', and 'Underweight' actions from firms like Stifel, Citigroup, and JP Morgan. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS of $6.79 and average revenue of $11.76 billion for the forward period, though without a specific price target, the implied upside or downside cannot be calculated. The target range, based on EPS estimates, spans from a low of $6.24 to a high of $7.36, indicating a relatively tight spread of about 17% which suggests moderate consensus on near-term earnings potential, but the recent pattern of analyst actions, including a downgrade from 'Buy' to 'Hold' by TD Cowen in October 2025, signals growing caution regarding the company's near-term prospects.
Bulls vs Bears: BAH Investment Factors
The investment debate for BAH is a classic clash between a compelling long-term strategic narrative and deteriorating near-term fundamentals. The bear case currently holds stronger evidence, anchored by concrete data showing a 10.2% YoY revenue decline and significant margin compression, which has driven a 39% stock price collapse and cautious analyst sentiment. However, the bull case is supported by a fortress balance sheet, strong cash generation, and a valuation that appears to discount substantial bad news. The single most important tension is whether the company's strategic positioning for high-margin AI/defense spending can translate into a tangible reacceleration of revenue and margin growth before investor patience is exhausted. The resolution of this tension—visible in future quarterly revenue growth figures—will dictate the stock's direction.
Bullish
- Strong Balance Sheet & Cash Flow: The company has a robust financial position with a low debt-to-equity ratio of 0.18 and a current ratio of 1.78, indicating ample liquidity. Furthermore, it generated $933 million in TTM free cash flow, providing significant flexibility for dividends, buybacks, and strategic investments without financial strain.
- Attractive Forward Valuation: BAH trades at a forward P/E of 12.59x, which is at the low end of its recent historical range (down from over 20x in 2024). This compression, coupled with a 39% stock price decline over the past year, suggests the market has already priced in significant pessimism, creating a potential value opportunity.
- Recent news highlights the Pentagon's aggressive pivot towards AI and autonomous systems, creating a long-term, high-margin revenue stream. As a trusted advisor with deep domain expertise, Booz Allen is strategically positioned to capture a significant share of this next-generation defense budget reallocation.
- High Return on Equity: The company demonstrates efficient use of shareholder capital with a trailing ROE of 77.0%. This exceptionally high figure, while partially a function of low equity due to share buybacks, underscores the firm's ability to generate substantial profits from its asset base.
Bearish
- Revenue Contraction & Negative Growth: The most recent quarterly revenue of $2.62 billion represents a 10.19% year-over-year decline, a concerning trend for a growth-oriented services firm. This sequential drop from $2.89 billion in the prior quarter indicates fundamental pressure on the core government contracting business.
- Significant Profitability Compression: Gross margin has contracted to 51.95% in Q3 2025, down from 53.64% in Q2 and 55.24% a year ago. This 330 basis point YoY decline, alongside a quarterly net margin of 7.63%, signals rising cost pressures or a less favorable business mix, directly impacting earnings power.
- Severe Technical Downtrend & Underperformance: The stock is down 39.07% over the past year and trades just 9.8% above its 52-week low of $68.84. It has significantly underperformed the SPY by 66.95% over the same period, reflecting deep-seated negative momentum and a lack of investor confidence despite recent stabilization attempts.
- Analyst Sentiment Turning Cautious: Recent institutional ratings include 'Hold', 'Neutral', 'Sell', and 'Underweight' from firms like Stifel, Citigroup, and JP Morgan. A specific downgrade from 'Buy' to 'Hold' by TD Cowen in October 2025 signals growing analyst caution regarding the company's near-term fundamental prospects.
BAH Technical Analysis
The stock is in a pronounced downtrend, having declined 39.07% over the past year, and is currently trading near the lower end of its 52-week range, approximately 9.8% above its 52-week low of $68.84 and 34.5% below its high of $120.05. This positioning near the lows suggests the stock is either presenting a deep value opportunity or is a falling knife, with the steep year-long decline indicating significant negative momentum and investor pessimism. Recent momentum shows a modest divergence, with the stock up 1.69% over the past month and 1.90% over the past three months, which could signal a tentative stabilization or a dead-cat bounce within the broader downtrend, especially given the stock's relative weakness versus the SPY, which is up 4.84% and 8.15% over the same periods, respectively. Key technical support is clearly defined at the 52-week low of $68.84, while resistance sits at the recent high near $102.23 from January; a sustained breakdown below support would likely trigger further selling, while a breakout above resistance could signal a more meaningful trend reversal, though the stock's low beta of 0.319 indicates it has been significantly less volatile than the broader market during this decline, which may limit the velocity of any potential recovery.
Beta
0.32
0.32x market volatility
Max Drawdown
-44.8%
Largest decline past year
52-Week Range
$69-$120
Price range past year
Annual Return
-25.9%
Cumulative gain past year
| Period | BAH Return | S&P 500 |
|---|---|---|
| 1m | +1.5% | +5.1% |
| 3m | +6.4% | +8.3% |
| 6m | -4.0% | +10.4% |
| 1y | -25.9% | +29.6% |
| ytd | -5.9% | +10.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BAH Fundamental Analysis
Revenue growth has turned negative, with the most recent quarterly revenue of $2.62 billion representing a 10.19% year-over-year decline, and a sequential drop from $2.89 billion in the prior quarter, indicating a concerning deceleration and potential pressure on the core government contracting business. The company remains profitable with net income of $200 million for the quarter, but profitability metrics are under pressure, as evidenced by a gross margin of 51.95%, which has compressed from 53.64% in the prior quarter and 55.24% a year ago, while the net margin for the quarter was 7.63%. Balance sheet and cash flow health appear robust, with a strong current ratio of 1.78, a very low debt-to-equity ratio of 0.18, and substantial free cash flow generation of $933 million on a trailing twelve-month basis, providing ample liquidity to fund operations, dividends, and share repurchases without reliance on external financing.
Quarterly Revenue
$2.6B
2025-12
Revenue YoY Growth
-0.10%
YoY Comparison
Gross Margin
+0.51%
Latest Quarter
Free Cash Flow
$933437000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BAH Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The forward PE ratio is 12.59x, based on estimated EPS of $6.79, while the trailing PE ratio is not calculable from the provided data (shown as 0), indicating the market is pricing in future earnings recovery. Peer comparison data for industry averages is not available in the provided dataset, preventing a direct sector premium/discount analysis. Historically, the stock's own valuation has compressed significantly; for instance, its PE ratio was 13.00x as of Q3 2025, down from levels above 20x in 2024, suggesting the stock is trading at the lower end of its recent historical range, which may reflect a discount for the current fundamental challenges or present a value opportunity if growth re-accelerates.
PE
11.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -45x~111x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's deteriorating profitability and revenue trajectory. The 10.2% YoY revenue decline in the latest quarter is a major red flag, indicating potential contract losses, delays, or budget pressures within its core federal government client base. Concurrently, gross margin compression of over 300 basis points year-over-year suggests rising costs or a shift to lower-margin work, directly threatening the earnings needed to support its valuation. While the balance sheet is strong, continued revenue contraction could quickly erode the high ROE and robust free cash flow generation that currently underpin the investment thesis.
Market & Competitive Risks are elevated due to the stock's significant underperformance and valuation compression. Trading at a forward P/E of 12.6x, down from levels above 20x, the stock faces valuation compression risk if growth does not re-emerge, potentially trapping it in a 'value trap' scenario. Its low beta of 0.319 indicates it has been a defensive laggard, but it remains exposed to sector rotation away from government services and potential budget austerity or reallocation within the Defense Department, despite the positive AI narrative. Competitive disruption from both traditional rivals and new tech entrants vying for the same AI contracts is a persistent threat.
Worst-Case Scenario involves a continuation of the current fundamental downtrend, where revenue declines accelerate and margin compression worsens, leading to consecutive earnings misses. This would trigger further analyst downgrades, a loss of dividend coverage confidence (payout ratio of 32.4%), and a breach of the key technical support at the 52-week low of $68.84. In this adverse scenario, the stock could realistically re-test its 52-week low, implying a downside of approximately -12.5% from the current price of $78.68. Given the stock's historical max drawdown of -44.8%, a more severe but less probable decline could approach the $60 range if the business outlook materially deteriorates.
FAQ
The key risks, in order of severity, are: 1) Operational Risk: Continued revenue contraction (-10.2% YoY) and margin compression (gross margin down 330 bps YoY). 2) Sentiment & Momentum Risk: The stock is in a severe downtrend, down 39% over the past year, and analyst sentiment is turning cautious with recent downgrades. 3) Market Risk: Despite a low beta of 0.32, the stock could remain a laggard if growth does not re-accelerate, becoming a 'value trap'. 4) Strategic Risk: Failure to materially capture the promised high-margin AI defense spending, leaving the positive narrative unfulfilled.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $78 and $95 as it consolidates, assuming flat revenue and stable margins. The Bull Case (25% probability) targets $100 to $115, driven by a return to growth and contract wins from the Pentagon's AI pivot. The Bear Case (15% probability) warns of a drop to the $68 to $75 range if fundamentals worsen. The Base Case is most likely, predicated on the assumption that the company's strong financials prevent a collapse, but growth remains elusive in the near term.
Based on its forward P/E of 12.59x, BAH appears fairly valued to slightly undervalued relative to its own historical trading range, which was above 20x in 2024. This compression reflects the market's discount for the company's current growth challenges. The valuation implies the market expects stagnant or negative earnings growth in the near term. Compared to sector peers, direct data is unavailable, but the low multiple combined with high ROE (77%) suggests the stock is not overvalued, but rather priced for the evident fundamental risks.
BAH is a speculative buy only for investors with a high risk tolerance and a long-term horizon. At a forward P/E of 12.6x, it appears undervalued relative to its history and its strong cash flow profile, offering a potential margin of safety. However, it is not a 'good buy' for most investors currently due to the concrete 10.2% YoY revenue decline and negative price momentum. It could become a good buy for value/GARP investors if upcoming quarterly results show a stabilization in revenue and margins.
BAH is unsuitable for short-term investment due to its high volatility within a downtrend, lack of near-term positive catalysts, and negative momentum. It is only suitable for a long-term investment horizon of 3-5 years, allowing time for the strategic AI/defense thesis to play out and for the company to potentially engineer a fundamental turnaround. The low beta of 0.32 suggests lower market-correlated volatility, but stock-specific risk is high. Investors should be prepared to hold through further potential downside and require a minimum holding period of 18-24 months to properly assess the turnaround thesis.